Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

AMLX

Amylyx Pharmaceuticals Inc

Sep 20 • 03:17PM ET

3.22

Dollar change +0.34
Percentage change 11.98	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VB VXF IBB VBK SMLF SCHA FYC IWC VHT

Index	-	P/E	-	EPS (ttm)	-2.45	Insider Own	39.55%	Shs Outstand	67.71M	Perf Week	23.09%
Market Cap	219.56M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	0.69%	Shs Float	41.15M	Perf Month	42.70%
Income	-165.87M	PEG	-	EPS next Q	-0.70	Inst Own	61.49%	Short Float	3.61%	Perf Quarter	81.18%
Sales	298.76M	P/S	0.73	EPS this Y	-623.81%	Inst Trans	32.34%	Short Ratio	0.92	Perf Half Y	12.37%
Book/sh	3.84	P/B	0.84	EPS next Y	52.14%	ROA	-42.22%	Short Interest	1.49M	Perf Year	-82.63%
Cash/sh	4.55	P/C	0.71	EPS next 5Y	-	ROE	-51.22%	52W Range	1.58 - 19.95	Perf YTD	-78.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-63.29%	52W High	-83.83%	Beta	-0.61
Dividend TTM	-	Quick Ratio	4.66	Sales past 5Y	2300.59%	Gross Margin	53.30%	52W Low	104.76%	ATR (14)	0.18
Dividend Ex-Date	Mar 28, 2018	Current Ratio	4.66	EPS Y/Y TTM	-100.06%	Oper. Margin	-51.85%	RSI (14)	78.64	Volatility	5.34% 5.95%
Employees	384	Debt/Eq	0.01	Sales Y/Y TTM	55.71%	Profit Margin	-55.52%	Recom	2.71	Target Price	4.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-439.59%	Payout	0.00%	Rel Volume	2.06	Prev Close	2.88
Sales Surprise	-109.59%	EPS Surprise	-46.58%	Sales Q/Q	-101.04%	Earnings	Aug 08 BMO	Avg Volume	1.62M	Price	3.22
SMA20	33.73%	SMA50	46.97%	SMA200	-50.99%	Trades		Volume	2,993,032	Change	11.98%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Downgrade	Mizuho	Buy → Neutral	$32 → $4
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral	$37 → $4
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27 → $4
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jan-03-24	Initiated	Robert W. Baird	Outperform	$37
Dec-12-23	Initiated	Deutsche Bank	Buy	$36
Jul-24-23	Upgrade	Goldman	Neutral → Buy	$45 → $49
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

Show Previous Ratings

Sep-09-24 07:17PM	Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +6.33% +5.56%
Sep-06-24 01:49AM	Director MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +7.73%
Aug-28-24 08:30AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-24 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration (Business Wire)
Aug-08-24 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results (Business Wire)
09:00AM	Loading…
Aug-05-24 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
04:32AM	EC grants orphan drug status for Amylyxs Wolfram treatment (Pharmaceutical Technology)
Aug-02-24 09:00AM	Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Jul-10-24 10:53AM	Amylyx to rebuild pipeline with $35m Phase III ready GLP-1RA acquisition (Clinical Trials Arena) +25.45%
07:00AM	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation (Business Wire)
03:00AM	Amylyx, with GLP-1 buy, doubles down on blood sugar drugs (BioPharma Dive)
Jul-09-24 04:01PM	Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide (Business Wire)
Jun-28-24 11:02AM	Amylyx ventures into metabolic diseases market with $35.1m deal (Pharmaceutical Technology)
Jun-04-24 09:00AM	Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-14-24 07:25AM	Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating (MT Newswires)
03:54PM	Loading…
May-10-24 03:54PM	Amylyx Pharmaceuticals Reports Q1 2024 Financial Results (GuruFocus.com) -7.14%
12:47PM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results (Business Wire)
May-08-24 09:00AM	Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference (Business Wire)
May-02-24 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-30-24 12:02PM	Trials to watch: Four ALS drugs to keep an eye on (Clinical Trials Arena)
Apr-10-24 03:14PM	Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder (Benzinga) -7.87%
09:00AM	Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome (Business Wire)
Apr-08-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024 (Business Wire)
Apr-04-24 01:20PM	Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70% (Zacks)
10:05AM	ALS drug will be pulled from US market after study showed patients didn't benefit (Associated Press Finance)
07:52AM	UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets (Reuters)
07:43AM	Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market (Barrons.com)
07:07AM	Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets (Reuters)
07:00AM	Loading…
07:00AM	Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy (Business Wire)
06:09AM	Amylyx to pull ALS drug from market in rare move (BioPharma Dive)
Apr-03-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire)
Apr-01-24 07:30PM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Mar-27-24 07:36AM	European study finds popular ALS drug ineffective (BioPharma Dive) +5.11%
Mar-25-24 02:33PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace) -7.85%
09:00AM	Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors (Business Wire)
Mar-13-24 10:00AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx (PR Newswire)
09:03AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-12-24 07:55AM	After surprise trial failure, ALS doctors brace for one less treatment option (BioPharma Dive) -9.47%
Mar-11-24 12:34PM	Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82% (Zacks) +13.10%
07:45AM	Amylyx CEOs look for a path forward following major setback (BioPharma Dive)
Mar-10-24 08:00AM	Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn. (The Wall Street Journal)
Mar-08-24 06:27PM	Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) -82.29% +13.10%
04:05PM	Amylyx Stock Wipes Out Nearly All Of Its Value, Crashing 82%, After Pivotal ALS Drug Failure (Investor's Business Daily)
11:30AM	Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work (Associated Press Finance)
10:20AM	Amylyxs ALS Drug Fails Trial, Raising Questions About Companys Future (Barrons.com)
10:12AM	Amylyx Stock Crashes 80% After Approved ALS Drug Fails Its Pivotal Test (Investor's Business Daily)
09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
09:26AM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
07:07AM	Amylyx's ALS drug fails in late-stage confirmatory study (Reuters)
07:00AM	Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS (Business Wire)
02:05AM	Amylyx ALS drug fails crucial study, putting companys future in doubt (BioPharma Dive)
Feb-27-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire) +8.20%
Feb-26-24 11:39AM	AMLX NEWS: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before the Lead Plaintiff Deadline (GlobeNewswire)
Feb-25-24 06:30AM	7 Oversold Russell 2000 Stocks to Add to Your February Buy List (InvestorPlace)
Feb-23-24 04:05PM	Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
10:30AM	AMYLYX SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options (GlobeNewswire)
10:10AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	AMLX Stockholders with Significant Losses Should Contact Robbins LLP for Information About Their Rights and Remedies Against Amylyx Pharmaceuticals, Inc. (Business Wire)
05:45AM	Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX (PR Newswire)
Feb-22-24 06:57PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire) +21.10%
04:10PM	Amylyx Stock Rockets As ALS Drug Tacks On Another Triple-Digit Quarter (Investor's Business Daily)
08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates (Zacks)
07:35AM	Amylyx Pharmaceuticals Inc (AMLX) Reports Robust Revenue Growth and Net Income for Full Year 2023 (GuruFocus.com)
07:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 05:45AM	Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire) -6.11%
Feb-19-24 12:40PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Feb-15-24 04:05PM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 (Business Wire)
02:13PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
09:00AM	Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference (Business Wire)
Feb-13-24 09:16PM	Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) -7.94%
12:58PM	Get Rich Quick With These 3 Biotech Stocks to Buy Now (InvestorPlace)
Feb-12-24 08:09PM	Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
11:09AM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Feb-08-24 09:00AM	Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Jan-26-24 03:57PM	3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024 (InvestorPlace)
Jan-21-24 01:16PM	3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 (InvestorPlace)
Jan-14-24 12:54PM	7 Healthcare Stocks Taking Medicine to the Next Level (InvestorPlace)
Jan-05-24 05:34AM	2 Biotech Stocks With Huge Catalysts in 2024 (Motley Fool)
Dec-26-23 07:02PM	5 Best IPO Stocks to Buy Heading into 2024 (Insider Monkey)
08:48AM	Is Amylyx (AMLX) Stock a Solid Choice Right Now? (Zacks)
Dec-22-23 09:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP) (Business Wire)
Dec-11-23 08:36AM	Implied Volatility Surging for Amylyx (AMLX) Stock Options (Zacks)
Dec-04-23 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS (Business Wire)
Nov-29-23 05:15PM	Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.19%
Nov-28-23 08:48AM	3 Top-Rated Biotech Stocks That Analysts Are Loving Now (InvestorPlace)
07:00AM	Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer (Business Wire)
Nov-27-23 09:00AM	RELYVRIO and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND (Business Wire)
Nov-21-23 09:00AM	Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-12-23 11:59AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 12:26AM	Q3 2023 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 05:04PM	Amylyx Crashes 32% On A Quarterly Report That Doesn't Bode Well For 2024 (Investor's Business Daily) -31.89%
12:12PM	Amylyx Crashes 27% As New ALS Drug Faces A Barrage Of Troubles (Investor's Business Daily)
08:05AM	Amylyx Pharmaceuticals Inc (AMLX) Reports Strong Q3 2023 Earnings with Significant Revenue Growth (GuruFocus.com)
07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-04-23 12:16PM	5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-02-23 10:00AM	Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks) +5.38%
09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023 (Business Wire)

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cohen Joshua B	Co-Chief Executive Officer	Sep 12 '24	Option Exercise	1.57	34,449	54,085	3,237,301	Sep 16 05:39 PM
FRATES JAMES M	Chief Financial Officer	Sep 12 '24	Buy	2.53	40,000	101,368	233,464	Sep 16 05:30 PM
Firestone Karen	Director	Sep 05 '24	Buy	2.13	50,000	106,590	55,000	Sep 09 04:05 PM
MILNE GEORGE M JR	Director	Sep 03 '24	Buy	2.20	100,000	219,800	858,571	Sep 05 07:26 PM
Quimi Daphne	Director	May 14 '24	Buy	1.89	2,750	5,184	2,750	May 16 07:37 PM
Quimi Daphne	Director	May 15 '24	Buy	1.89	2,250	4,252	5,000	May 16 07:37 PM
Mazzariello Gina	Chief Legal Officer	May 15 '24	Sale	1.88	10,455	19,654	151,477	May 16 07:36 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	3,023,002	Mar 07 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 05 '24	Sale	18.73	4,135	77,440	2,959,308	Mar 07 04:05 PM
FRATES JAMES M	Chief Financial Officer	Mar 05 '24	Sale	18.73	1,792	33,560	134,784	Mar 07 04:05 PM
Mazzariello Gina	Chief Legal Officer	Mar 05 '24	Sale	18.73	1,540	28,841	81,372	Mar 07 04:05 PM
Mazzariello Gina	Chief Legal Officer	Feb 23 '24	Sale	18.76	2,838	53,231	46,245	Feb 27 05:59 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 09 '24	Sale	16.33	5,841	95,372	2,836,776	Jan 11 05:11 PM
FRATES JAMES M	Chief Financial Officer	Jan 09 '24	Sale	16.33	2,716	44,347	112,035	Jan 11 05:11 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 09 '24	Sale	16.33	5,841	95,372	2,900,470	Jan 11 05:10 PM
Yeramian Patrick D	Chief Medical Officer	Jan 09 '24	Sale	16.33	2,812	45,915	205,605	Jan 11 05:04 PM
Olinger Margaret	Chief Commercial Officer	Dec 27 '23	Option Exercise	0.37	25,000	9,250	276,108	Dec 29 04:07 PM
Firestone Karen	Director	Dec 15 '23	Buy	14.97	4,000	59,880	5,000	Dec 19 04:37 PM
Cohen Joshua B	Co-Chief Executive Officer	Nov 16 '23	Option Exercise	1.57	63,694	100,000	2,906,311	Nov 20 08:20 PM

Open in Screener

KZR

Kezar Life Sciences Inc

Sep 20 • 03:17PM ET

0.5737

Dollar change -0.0089
Percentage change -1.53	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

KZR Kezar Life Sciences Inc daily Stock Chart

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-1.35	Insider Own	14.94%	Shs Outstand	72.78M	Perf Week	0.65%
Market Cap	41.86M	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-0.06%	Shs Float	62.06M	Perf Month	-9.14%
Income	-98.57M	PEG	-	EPS next Q	-0.32	Inst Own	50.29%	Short Float	1.54%	Perf Quarter	-10.75%
Sales	7.00M	P/S	5.98	EPS this Y	12.38%	Inst Trans	4.51%	Short Ratio	1.80	Perf Half Y	-40.55%
Book/sh	2.07	P/B	0.28	EPS next Y	3.67%	ROA	-44.47%	Short Interest	0.95M	Perf Year	-49.68%
Cash/sh	2.25	P/C	0.25	EPS next 5Y	-	ROE	-51.48%	52W Range	0.54 - 1.25	Perf YTD	-39.44%
Dividend Est.	-	P/FCF	-	EPS past 5Y	9.06%	ROI	-60.68%	52W High	-54.10%	Beta	0.20
Dividend TTM	-	Quick Ratio	9.58	Sales past 5Y	0.00%	Gross Margin	84.59%	52W Low	6.64%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	9.58	EPS Y/Y TTM	-18.69%	Oper. Margin	-1422.01%	RSI (14)	45.17	Volatility	4.21% 5.59%
Employees	58	Debt/Eq	0.12	Sales Y/Y TTM	-	Profit Margin	-1408.11%	Recom	2.00	Target Price	7.33
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	11.83%	Payout	-	Rel Volume	0.25	Prev Close	0.58
Sales Surprise	-100.00%	EPS Surprise	6.16%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	530.52K	Price	0.57
SMA20	-2.79%	SMA50	-6.02%	SMA200	-25.72%	Trades		Volume	116,516	Change	-1.53%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$4
Mar-16-23	Downgrade	William Blair	Outperform → Mkt Perform
Dec-08-21	Initiated	Wells Fargo	Overweight	$19
Jul-16-18	Initiated	William Blair	Outperform
Jul-16-18	Initiated	Wells Fargo	Outperform	$30
Jul-16-18	Initiated	Jefferies	Buy

Sep-04-24 04:01PM	Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-14-24 11:13AM	Kezar stalls solid tumour trial to focus on autoimmune disease candidate (Pharmaceutical Technology) +5.05%
Aug-13-24 04:02PM	Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-10-24 04:01PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +10.28%
Jun-07-24 05:59PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +5.07%
04:01PM	Loading…
May-29-24 04:01PM	Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-09-24 10:57PM	KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024 (InvestorPlace) -5.42%
04:01PM	Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-06-24 04:05PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Apr-08-24 05:38PM	13 Best Penny Stocks to Buy According to Billionaire Ken Griffin (Insider Monkey)
04:01PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Mar-27-24 04:30PM	From Pennies to Fortunes: 3 Stocks Set to Make Millionaires (InvestorPlace)
Mar-16-24 06:56AM	Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026 (InvestorPlace)
Mar-14-24 09:54PM	KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023 (InvestorPlace) -6.59%
04:01PM	Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update (Business Wire)
04:05PM	Loading…
Mar-08-24 04:05PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Feb-28-24 04:01PM	Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference (Business Wire) +7.27%
Feb-26-24 06:30PM	Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis (Business Wire) +8.18%
Feb-25-24 02:12PM	3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond (InvestorPlace)
Feb-02-24 05:37AM	3 Penny Stocks Poised for an Unbelievable 1,000% Jump (InvestorPlace)
Dec-18-23 08:51AM	Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth (InvestorPlace)
Nov-21-23 04:01PM	Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 04:01PM	Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire) +7.60%
Nov-03-23 04:03PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +6.25%
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey)
Oct-09-23 05:56PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +13.43%
Oct-04-23 09:32AM	Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce (Zacks)
Oct-03-23 04:10PM	Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer (Business Wire) -9.57%
Sep-20-23 06:30PM	Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia (Business Wire)
04:01PM	Loading…
Aug-31-23 04:01PM	Kezar Life Sciences to Participate in Three Upcoming Investor Conferences (Business Wire) -8.59% +5.37%
Aug-10-23 04:01PM	Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire) -26.34%
Aug-04-23 04:03PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-07-23 04:01PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-09-23 04:01PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
May-31-23 07:00AM	Kezar Life Sciences to Participate in the Jefferies Healthcare Conference (Business Wire)
May-11-23 04:01PM	Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Apr-05-23 04:01PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -13.87% +6.36%
Mar-14-23 04:01PM	Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update (Business Wire) -11.00%
Mar-13-23 07:00AM	Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023 (Business Wire) +10.99%
Mar-06-23 07:00AM	Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023 (Business Wire)
Mar-03-23 06:17PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Mar-01-23 04:01PM	Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference (Business Wire) -10.73%
Feb-06-23 04:01PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
11:44AM	A Kezar Life Sciences, Inc. (NASDAQ:KZR) insider increased their holdings by 9.9% last year (Simply Wall St.)
Jan-26-23 06:44AM	Daily Vickers Top Buyers & Sellers for 01/26/2023 (Argus Research)
Jan-13-23 04:01PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 (Argus Research)
Jan-04-23 04:01PM	Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-07-22 04:01PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Nov-14-22 07:00AM	Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022 (Business Wire)
Nov-11-22 04:01PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +5.39%
Nov-10-22 04:01PM	Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire) +13.15%
Nov-09-22 04:01PM	Kezar Life Sciences to Participate in Two Upcoming Investor Conferences (Business Wire) -8.71%
Nov-03-22 10:00AM	Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASNs Kidney Week 2022 Annual Meeting (Business Wire)
Oct-14-22 07:00AM	Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrologys Kidney Week 2022 Annual Meeting (Business Wire)
Oct-06-22 04:01PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -6.16%
Oct-03-22 04:01PM	Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis (Business Wire)
Sep-29-22 04:05PM	Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 (Business Wire)
Sep-02-22 04:30PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Sep-01-22 07:00AM	Kezar Life Sciences to Participate in Three Upcoming Investor Conferences (Business Wire)
Aug-30-22 12:10PM	A Kezar Life Sciences, Inc. (NASDAQ:KZR) insider increased their holdings by 9.9% last year (Simply Wall St.)
Aug-11-22 04:01PM	Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire) +6.05%
Aug-03-22 04:30PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-18-22 09:55AM	Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High? (Zacks) -5.45%
Jul-11-22 04:30PM	Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position (Business Wire)
Jul-08-22 02:42PM	Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating (Investor's Business Daily)
Jul-07-22 04:30PM	Kezar Life Sciences to Present at the William Blair Biotech Focus Conference (Business Wire)
Jul-06-22 04:30PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-30-22 01:08PM	Biotech ETF Tops in June: 5 Stocks That Outperform (Zacks)
09:55AM	Wall Street Analysts Think Kezar Life Sciences, Inc. (KZR) Could Surge 135%: Read This Before Placing a Bet (Zacks)
Jun-28-22 03:57PM	Wells Fargo Beefs Up Kezar Life Price Target - Read Why (Benzinga) +43.43%
11:58AM	Why Kezar Life Sciences Stock Is Crushing It Today (Motley Fool)
10:23AM	Kezar (KZR) Doubles on Promising Kidney Disorder Study Data (Zacks)
09:58AM	Healthcare Breakthroughs: KZR, NMLSF, AGRX, LMLLF Report Latest Advances in Novel Therapeutics for Inflammatory Diseases, Oncology, and Autism (GlobeNewswire)
Jun-27-22 09:31PM	Early lupus patient data sends Kezar Life Sciences' stock soaring after-hours (American City Business Journals)
04:01PM	Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis (Business Wire)
11:46AM	Billionaire Israel Englander Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks)
Jun-10-22 09:35AM	Down 10.7% in 4 Weeks, Here's Why Kezar Life Sciences, Inc. (KZR) Looks Ripe for a Turnaround (Zacks) -7.10%
Jun-03-22 04:30PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-01-22 06:15AM	3 Biotech Stocks to Buy Before They Boom (InvestorPlace)
May-23-22 09:55AM	Kezar Life Sciences, Inc. (KZR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
09:35AM	After Plunging 59.3% in 4 Weeks, Here's Why the Trend Might Reverse for Kezar Life Sciences, Inc. (KZR) (Zacks)
May-12-22 04:01PM	Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-11-22 09:32AM	Health Check: How Prudently Does Kezar Life Sciences (NASDAQ:KZR) Use Debt? (Simply Wall St.)
08:59AM	10 Stocks to Invest in Under $20 According to Michael Castors Sio Capital (Insider Monkey)
May-10-22 08:38AM	Should You Buy Kezar (KZR) Ahead of Earnings? (Zacks)
May-05-22 04:30PM	Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -7.33%
May-04-22 03:57PM	Wells Fargo Analyst Has Questions On Kezar's Lupus Nephritis Data Readout, Stock Plunges (Benzinga) -43.51%
05:57AM	Kezar Life's Lead Asset Fails To Top Placebo In Muscle Inflammation Disease (Benzinga)
May-03-22 04:01PM	Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis (Business Wire)
Apr-15-22 04:05PM	Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Apr-05-22 07:00AM	VOX PROVIDES DEVELOPMENT & EXPLORATION UPDATES (PR Newswire)
Mar-24-22 11:03AM	3 Strong Buy Stocks Showing Strong Insider Interest (TipRanks)
Mar-23-22 04:58PM	Possible turnaround for Kezar Life Sciences, Inc. (NASDAQ:KZR) insiders, still down US$17k after a US$1.3m shopping spree (Simply Wall St.) +9.48%
Mar-18-22 12:42PM	Stocks Mostly Higher As FedEx, Biotech, Chipmakers Report News, Earnings (Investor's Business Daily)
Mar-17-22 04:01PM	Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update (Business Wire)
Mar-02-22 07:00AM	Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference (Business Wire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schiller Mark C.	Chief Legal Officer	Jul 02 '24	Sale	0.58	6,688	3,879	33,007	Jul 26 05:41 PM

AMLX

Amylyx Pharmaceuticals Inc

KZR

Kezar Life Sciences Inc

Upgrade your FINVIZ experience